Search Results
| Year | ID | Type | Category | Title | Authors |
|---|
| 2022 | QOL20 | Poster | Quality of Life and Outcomes |
Avoidant Coping Predicts Quality of Life for Persons with Multiple Sclerosis with High Cognitive Reserve |
Samantha M Vervoordt, M.S., Department of Psychology, The Pennsylvania State University, State College, PA and Peter A Arnett, Ph.D., Department of Psychology, Pennsylvania State University, State College, PA |
| 2022 | QOL21 | Poster | Quality of Life and Outcomes |
Patient-Reported Outcomes for Patients Treated with Peginterferon Beta-1a: Plegridy Observational Program Interim Analysis |
Sibyl Wray, MD1, Marco Salvetti, MD2, Gereon Nelles, MD3, Nydjie Grimes, MPH, BA4, Nicholas Belviso, PhD5 and Thijs Koster, MSc5, (1)Hope Neurology MS Center, Knoxville, TN, (2)Sapienza University, S. Andrea Hospital, Rome, Italy, (3)Neurology, NeuroMed Campus Hohenlind, Cologne, Germany, (4)Biogen, at the time of this analysis, Cambridge, MA, (5)Biogen, Cambridge, MA |
| 2022 | QOL22 | Poster | Quality of Life and Outcomes |
Impact of Cognitive Impairment on Quality of Life and Work Productivity of Relapsing-Remitting Multiple Sclerosis Patients: A Systematic Literature Review |
Lea Achrafie, MS1, Joelle Constantin, MS2, Maud Pacou, MS3, Jinender Kumar, MS4 and Tom Tencer, PhD4, (1)Amaris Consulting, Toronto, ON, Canada, (2)Amaris Consulting, Montreal, QC, Canada, (3)Amaris Consulting, Paris, France, (4)Bristol Myers Squibb, Princeton, NJ |
| 2022 | REH07 | Poster | Rehabilitation Posters |
Rhythmic Transcranial Magnetic Stimulation (rTMS) As a Tool for Reducing Overall Levels of Fatigue in Patients with Multiple Sclerosis |
Alice E Dias, Dr1, Demetrios C Agourakis, Medical Student2, Giovanna P Vidigal, Physiotherapist3, Andre V S Caetano, Physical educator3, Juliana AR Telles, MSc4, Bruna H Sciarinni, Physiotherapist4, Mauricio O Bando, Neuropsychologist5, Carlos B M Monteiro, Dr3 and Talita D Silva, Dr6, (1)Scientific Research, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil, (2)Medicine, Faculty of Medicine, University City of Sa?o Paulo (UNICID), São Paulo, Brazil, (3)University of São Paulo School of Arts, Sciences and Humanities (EACH), São Paulo, Brazil, (4)Physiotherapy, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil, (5)Neurorehabilitation, ABEM – Brazilian Multiple Sclerosis Association, Sao Paulo, Brazil, (6)Sao Paulo University, Sao Paulo, Brazil |
| 2022 | REH08 | Poster | Rehabilitation Posters |
Translingual Neurostimulation By Portable Neuromodulation Stimulator System As a New Rehabilitation Therapy for Improving Gait in People with Multiple Sclerosis |
Antonella Favit-VanPelt, MD, PhD1, Kim Skinner, PT, DPT1, Greg Maislin, PhD2, Nicole Strachan, BHK, MSc. P.Kin1 and Lola Abhulimen, MBA1, (1)Helius Medical Technologies, Newtown, PA, (2)Biomedical Statistical Consulting, Wynnewood, PA |
| 2022 | REH09 | Poster | Rehabilitation Posters |
Pilot Study: Cognitive Rehabilitation Via Telehealth Yields Impressive Outcomes |
Betty Mathew, SLP, Multiple Sclerosis Outpatient Rehabilitation, Shepherd Center, Atlanta, GA |
| 2022 | REH10 | Poster | Rehabilitation Posters |
Do Device-Measured Physical Activity and Sedentary Behavior Differ By Depression Symptom Status in Persons with MS? |
Catherine D Jones, MSPH1, Brenda Jeng, MS2, Petra Silac, B.S.2 and Rob Motl, PhD1, (1)Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL |
| 2022 | REH11 | Poster | Rehabilitation Posters |
Strategies to Help Resistant People Improve Gait |
Clare T Hartigan, PT, MPT, Multiple Sclerosis Outpatient Rehabilitation, Shepherd Center, Atlanta, GA |
| 2022 | REH12 | Poster | Rehabilitation Posters |
Case Report: Blood Flow Restriction and Therapeutic Exercise for a Patient with Multiple Sclerosis and Advanced Disability |
Evan T Cohen, PT, MA, PhD, NCS, Rehabilitation and Movement Sciences, Rutgers, The State University of New Jersey, Blackwood, NJ, Hannah Dwight, PT, DPT, PhD, Neurology, University of Colorado, Aurora, CO, Johnny Owens, BS, MPT, Owens Recovery Science, San Antonio, TX, Michael Bade, Michael Bade PT, DPT, PhD, OCS, FAAOMPT, University of Colorado, Denver, CO, Rashelle Hoffman, PT, DPT, PhD, Department of Physical Therapy, Creighton University, Omaha, NE and Mark M Manago, PT, PhD, Department of Neurology, University of Colorado School of Medicine, Aurora, CO |
| 2022 | REH13 | Poster | Rehabilitation Posters |
Effects of in-Person, Telehealth, and Combined Wellness Programs on Functional Outcomes in Individuals with MS: A Retrospective Cohort Study Protocol |
Emily Gard, SPT1, Jordan Lutz, SPT2 and Hina Garg, PT, MS, PhD, NCS1, (1)Rocky Mountain University of Health Professions, Provo, UT, (2)Salt Lake City, UT |
| 2022 | REH14 | Poster | Rehabilitation Posters |
Transcranial Magnetic Stimulation Associated with Physical Therapy on Balance of People with Multiple Sclerosis: A PILOT Study |
Juliana AR Telles, MSc1, Alice E Dias, Dr2, Bruna H Sciarini, physiotherapy3, Mauricio O Bando, Neuropsychologist4, Demetrios C Agourakis, Medical Student5, Giovanna Vidigal, physicaltherapist6, Carlos BM Monteiro, physicaltherapist6, Andre V S Caetano, Physical educator7 and Talita Dias, physicaltherapist6, (1)Physiotherapy, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil, (2)Scientific Research, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil, (3)physiotherapy, Brazilian Association of Multiple Sclerosis, São Paulo, Brazil, (4)Neurorehabilitation, ABEM – Brazilian Multiple Sclerosis Association, Sao Paulo, Brazil, (5)Medicine, Faculty of Medicine, University City of Sa?o Paulo (UNICID), São Paulo, Brazil, (6)Universidade de São Paulo, São Paulo, Brazil, (7)University of São Paulo School of Arts, Sciences and Humanities (EACH), São Paulo, Brazil |
| 2022 | REH15 | Poster | Rehabilitation Posters |
Telerehabilitation on COVID 19 Pandemic Period Affecting Quality of Life and Fatigue of People with Multiple Sclerosis |
Juliana AR Telles, physicaltherapist1, Alice E Dias, Dr2, Anna ELISA Moraes, physicaltherapist3, Francis Fávero, physicaltherapist4 and Acary Bulle, doctor3, (1)neurologia, Associação Brasileira de Esclerose Múltipla, São Paulo, Brazil, (2)Scientific Research, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil, (3)universidade federal de são paulo, são paulo, Brazil, (4)neurologia, universidade federal de são paulo, São Paulo, Brazil |
| 2022 | REH16 | Poster | Rehabilitation Posters |
Combining Telerehabilitation with Functional Electrical Stimulation for Walking for People with Multiple Sclerosis: A Pilot Study |
Lisa C Donahue, MPT, NCS1, Pierre Karashchuk, BA1,2, Elie Celnikier, ME1, Mohammed Aashyk Mohaiteen Hebsur Rahman, MS1, Juan M Rodriguez, BS1, Andrew Ekelem, PhD1 and Pierluigi Mantovani, BA1, (1)Evolution Devices, Berkeley, CA, (2)Neuroscience Program, University of Washington, Seattle, WA |
| 2022 | REH17 | Poster | Rehabilitation Posters |
Occupational Therapy Interventions for Job Retention for Individuals with Multiple Sclerosis: A Case Study |
Rebecca Cunningham, OTD, OTR/L, MSCS and Kayla Gan, MA, OTR/L, Chan Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA |
| 2022 | REH18 | Poster | Rehabilitation Posters |
Forced Exercise Training for Persons with Multiple Sclerosis |
Ryan M Love, MS, Heritage College of Osteopathic Medicine, Ohio University, Cleveland, OH, Alexis Skolaris, BA, Cleveland Clinic, Cleveland, OH, Amanda Penko, PhD, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, Francois Bethoux, MD, Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH and Susan M Linder, DPT, Department of Physical Medicine and Rehabilitation, Cleveland Clinic, Cleveland, OH |
| 2022 | REH19 | Poster | Rehabilitation Posters |
Professional Workforce Development for Rehabilitation in MS |
Suzanne M Carron, OTR1, Marissa A Barrera, MS, MPhil, MSCS, CCC-SLP, PhD2, Valerie J Block, PT, DPTSc3, Salim Chahin, MD, MSCE4, Angelina Ciavarella, PT, DPT, NCS5, Rebecca Cunningham, OTD, OTR/L, MSCS6, Carleigh Dabritz, MS OTR/L, CPAM7, Meredith Drake, PT, DPT, NCS8, Elissa C Held Bradford, PT, PhD, NCS, MSCS9, Brian Hutchinson, PT, MSCS10, Rola A Mahmoud, MD11, Shaina Meyer, OTR/L, MSCS12, Katelyn Michtich, MBA13, Kelli Reiling Ott, OTD, OTR/L, MSCS14, Victoria Pavelko, CCC-SLP15, Kirsten Potter, PT, DPT, MS16, Emily Reilly, CPT17 and Alexius Sandoval, MD8, (1)Advocacy and Healthcare Access, National Multiple Sclerosis Society, Saint Louis, MO, (2)Speech Language and Hearing Sciences, Katz School for Science & Health, Yeshiva University, New York, NY, (3)Post-Doctoral Fellow within UCSF Physical Therapy, University of California San Francisco, San Francisco, CA, (4)Department of Neurology, Washington University in St. Louis, St. Louis, MO, (5)Physical Therapy, Oregon Health Sciences University, Portland, OR, (6)Chan Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA, (7)Physical Medicine and Rehabilitation, John Hopkins, Baltimore, MD, (8)Physical Medicine and Rehabilitation, Johns Hopkins, Baltimore, MD, (9)Department of Physical Therapy and Athletic Training, Saint Louis University, St. Louis, MO, (10)Multiple Sclerosis Achievement Center, Dignity Health, Sacramento, CA, (11)Neurology, Saint Luke’s Marion Bloch Neuroscience Institute, Comprehensive MS center, Kansas City, MO, (12)Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, (13)Advocacy and Healthcare Access, National Multiple Sclerosis Society, Southern California & Nevada Chapter, Los Angeles, CA, (14)Occupational Therapy Education, The University of Kansas Medical Center, Kansas City, KS, (15)Virginian Rehab & Wellness Inc, Chantilly, VA, (16)Department of Physical Therapy Education, Rockhurst University, Kansas City, MO, (17)Advocacy and Healthcare Access, National Multiple Sclerosis Society, Washington, DC |
| 2022 | SYM01 | Poster | Symptom management |
Variability of Spasticity in Multiple Sclerosis – Results from SEEN-MSS, a Large-Scale, Self-Reported Survey |
Barry Hendin, MD1, Ben W Thrower, MD2, Scott D. Newsome, DO, MSCS, FAAN, FANA3, Robert Chinnapongse, MD4, Sherry Danese, BS, MBA5 and Jenifer Patterson, ARNP, MSCN4, (1)Center for Neurology and Spine, Phoenix, AZ, (2)Crawford Research Institute, Shepherd Center, Atlanta, GA, (3)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (4)Jazz Pharmaceuticals, Carlsbad, CA, (5)Outcomes Insights, Agoura Hills, CA |
| 2022 | SYM02 | Poster | Symptom management |
Current Treatment for Spasticity in Multiple Sclerosis – Satisfaction, Limitations, and Future Directions |
Barry Hendin, MD1, Ben W Thrower, MD2, Scott D. Newsome, DO, MSCS, FAAN, FANA3, Robert Chinnapongse, MD4, Sherry Danese, BS, MBA5 and Jenifer Patterson, ARNP, MSCN4, (1)Center for Neurology and Spine, Phoenix, AZ, (2)Crawford Research Institute, Shepherd Center, Atlanta, GA, (3)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (4)Jazz Pharmaceuticals, Carlsbad, CA, (5)Outcomes Insights, Agoura Hills, CA |
| 2022 | SYM03 | Poster | Symptom management |
Fatigue in Active and Nonactive Primary and Secondary Progressive Multiple Sclerosis Patients in the United States |
Crystal Watson, MS1, Natalia Sadetsky, MD, PhD1, Dhanalakshmi Thirumalai, PhD, MPH2, Arie Barlev, PharmD, MS1, Nikisha Grant, BSc, MSc3, Eddie Jones, BA3, Sasha Bogdanovich, MD, PhD2 and Kiren Kresa-Reahl, MD2, (1)Atara Biotherapeutics, South San Francisco, CA, (2)Atara Biotherapeutics, Thousand Oaks, CA, (3)Adelphi Real World, Bollington, Cheshire, United Kingdom |
| 2022 | SYM04 | Poster | Symptom management |
Post Hoc Analysis of Nabiximols Efficacy By Concomitant Medication Use in 2 Enriched Placebo-Controlled Randomized Clinical Trials (RCTs) |
Faria Amjad, MD1, Aaron L Boster, MD2, Javier Carod Artal, MD3, Robert Chinnapongse, MD4, Daniel Checketts, MSc5, Peyman Adjamian, MD5 and Joshua R. Steinerman, MD4, (1)Georgetown University, Washington, DC, (2)The Boster Center for Multiple Sclerosis, Columbus, OH, (3)Raigmore Hospital, NHS Highlands, Scotland, United Kingdom, (4)Greenwich Biosciences, Inc., Carlsbad, CA, (5)GW Research Ltd, Cambridge, United Kingdom |
| 2022 | SYM05 | Poster | Symptom management |
Nabiximols Efficacy in MS Spasticity: Treatment Effects on Spasticity Numeric Rating Scale Score and Muscle Spasm Frequency in 2 Randomized Clinical Trials |
Sajida Javaid, CCST, FRCP, FRCS, FCPS1, Fred D. Lublin, MD2, Jacqueline A Nicholas, MD, MPH3, Sylvia Klineova, MD2, Joris Berwaerts, MD4, Robert Chinnapongse, MD4, Daniel Checketts, MSc5 and Joshua R. Steinerman, MD4, (1)Bridgend Clinic, Wales, United Kingdom, (2)Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, (3)OhioHealth Multiple Sclerosis Center, Columbus, OH, (4)Greenwich Biosciences, Inc., Carlsbad, CA, (5)GW Research Ltd, Cambridge, United Kingdom |
| 2022 | Poster |
Perceptions of Newly Diagnosed Persons with Multiple Sclerosis on Exercise and Physical Activity – a Qualitative Study |
David A Henning, PhD1, Lori Quinn, PT, EdD2, Andre Cabalang, BS3 and Nora E Fritz, PhD, PT, DPT, NCS1, (1)Neuroimaging and Neurorehabilitation Laboratory, Wayne State University, Detroit, MI, (2)Biobehavioral Sciences, Teachers College Columbia University, New York, NY, (3)Physical Therapy, Wayne State University, Detroit, MI |
| 2022 |
Effectiveness of Different Dietary Approaches on Fatigue and Quality of Life in People with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis of Randomized Trials |
Linda G. Snetselaar, PhD, RDN1, Joshua Cheek, BA2, Sara Shuger Fox, PhD2, Heather Healey, MA, MLS, AHIP3, Marin Schweizer, PhD4, Wei Bao, MD, PhD5, John A Kamholz, MD, PhD6 and Tyler J. Titcomb, PhD, RDN4, (1)Department of Epidemiology, University of Iowa, Iowa City, IA, (2)Central College, Pella, IA, (3)Hardin Library for the Health Sciences, University of Iowa, Iowa City, IA, (4)Department of Internal Medicine, University of Iowa, Iowa City, IA, (5)University of Science and Technology of China, Hefei, China, (6)Neurology, University of Iowa, Iowa City, IA |
| 2022 |
Comorbidity between Multiple Sclerosis and Idiopathic Intracranial Hypertension: A Retrospective Cohort Study |
Jay B Lusk, BSc1, Ailin Song, BA1, Paige E Sutton, MD2 and Suma Shah, MD2, (1)Duke University School of Medicine, Durham, NC, (2)Department of Neurology, Duke University, Durham, NC |
| 2022 |
Multiple Sclerosis Patients Have Higher Full Employment Rates Than Other Patients Following in the Neuroimmunology Clinic. |
Delaney Cairns, BS1, Mokshal H Porwal, BSc1, Amber Salter, PhD2, Samantha O’Dell, BA1, DeAnna Finnessy, MA1, Camila Ishueva, BS1, Murali Palathinkara, BS1, Abrahim N Razzak, BS1 and Ahmed Z Obeidat, MD, Ph.D.1, (1)Neurology, Medical College of Wisconsin, Milwaukee, WI, (2)Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX |
| 2021 | Late-Breaking | Psychosocial factors |
Connect Trial of Online Professional Support Groups for Black and Latinx People Living with MS |
V. M. Leavitt, A. Cohen, J. E. Duncan, and S. Magosin |
| 2021 | Late-Breaking | Disease-modifying therapy |
Dimethyl Fumarate Is Associated with Lower Rates of Infection and Lower Infection-Related Healthcare Costs When Compared with Ocrelizumab |
J. Nicholas, M. Gudesblatt, M. Garabedian, N. Belviso, C. Shen, C. Geremakis, S. L. Shankar, J. P. Mendoza, and J. B. Lewin |
| 2021 | Late-Breaking | Self-care |
Patient-Centered Education and Care Coordination Initiative to Improve Self-Management Skills in Latinos with Multiple Sclerosis |
A. L. Castro |
| 2021 | Late-Breaking | Disease-modifying therapy |
US Real World Experience Switching from Infusion and S1P Therapies to Cladribine Tablets: A Single Center Study |
R. Dukkipati |
| 2021 | Late-Breaking | Disease-modifying therapy |
Early Experience with Cladribine Tablets in an Aging Patient Population |
D. Sellers and D. Negroski |
| 2021 | Late-Breaking | Disease-modifying therapy |
Humoral and T-Cell Responses to Sars-Cov-2 Vaccination in Multiple Sclerosis Patients Treated with Ocrelizumab |
J. D. Katz, A. J. Bouley, E. S. Lathi, E. A. Douglas, R. M. M. Jungquist, and I. L. O’Shea |
| 2021 | Late-Breaking | Case Reports/Case Series |
Multiple Sclerosis Diagnosis: Challenges in Telehealth |
L. Shiver |
| 2021 | Late-Breaking | Quality of life and outcomes |
Patient Practices and Experiences during COVID-19 Among Individuals across the United States Enrolled in MS Lifelines Patient Support Program |
J. Nicholas, D. S. Mackie, H. Costantino, L. Lebson, E. Mulvihill, and A. L. Philips |
| 2021 | Late-Breaking | Disease-modifying therapy |
Sustained B-Cell Depletion By Inebilizumab Is Associated with Decreased Disease Activity in Aquaporin-4 Seropositive Neuromyelitis Optica Spectrum Disorder |
J. L. Bennett, O. Aktas, W. A. Rees, M. A. Smith, D. She, S. J. Pittock, B. G. Weinshenker, F. Paul, D. M. Wingerchuk, H. J. Kim, E. Katz, M. Levy, and B. A. Cree |
| 2021 | Late-Breaking | Disease-modifying therapy |
The Humoral Response to Sars-COV-2 Vaccines in MS Patients: Impact of Dmt, Lymphocyte Count, Immunoglobulins, and Vaccine Type |
H. Abboud, C. Jakubecz, S. Woodson, and A. Serra |
| 2021 | Late-Breaking | Disease-modifying therapy |
Interim Results of Open-Label Multicenter Phase 4 Study Assessing Immune Response to Influenza Vaccine in Patients with Relapsing Multiple Sclerosis Treated with Ofatumumab |
J. Gitt, E. B. Lucassen, J. Stankiewicz, X. Meng, and B. Weinstock-Guttman |
| 2021 | Late-Breaking | Disease-modifying therapy |
Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab |
K. Hellwig, B. Yamout, R. Bove, P. Katkuri, U. S. Topphoff, D. Stoneman, R. Zielman, R. Pingili, and M. Houtchens |
| 2021 | Late-Breaking | Epidemiology and genetics |
Geographic Variance of MS Prevalence in the United States |
M. Hittle, G. Cutter, M. T. Wallin, W. J. Culpepper II, A. M. Langer-Gould, R. A. Marrie, W. Kaye, L. Wagner, N. LaRocca, and L. Nelson |
| 2021 | Late-Breaking | Neuroimmunology and disease models |
Temporal Trends in Humoral and Cellular Immune Responses to Sars-Cov-2 mRNA Vaccines Among Multiple Sclerosis Patients Treated with Natalizumab, Ocrelizumab or Fumarates |
P. Repovic, J. Choi, S. Hong, J. Reola, J. Bowen, P. Qian, J. Heath, and J. Goldman |
| 2021 | Late-Breaking | Methods of Care |
Evaluating the Impact of Administering Ocrelizumab Via a Home Infusion on Safety and Patient Reported Outcomes |
K. V. Nair |